Recent Updates
Recently added Catalysts
CODX Positive Sentiment Score: 80/100

Co-Dx™ awarded $2.3M from Bill & Melinda Gates Foundation

Key Takeaway: Co-Dx has been awarded $2.3 million in grants from the Bill & Melinda Gates Foundation. The funding includes $1.3 million for tuberculosis tests and $987,000 for HPV tests. These grants will help complete the tests for the Co-Dx PCR Home™ platform, targeting priority global markets.
Price reaction · baseline $40.5 (2023-07-17 close) · hit pre-market · 1 other CODX headline(s) in the window, move may be shared
day 0 close · peak
+4.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • Co-Dx received significant funding from a reputable foundation.
  • The grants will support critical health tests for tuberculosis and HPV.
  • The funding is aimed at priority global markets, enhancing accessibility.

Full Press Release Details

In July 2023, Co-Dx was awarded two grants from the Bill & Melinda Gates Foundation totaling $2.3 million for its tuberculosis (TB) and human papillomavirus (HPV) tests.
The $1.3 million grant for tuberculosis and $987,000 grant for HPV will be applied toward completing the tests for the Co-Dx PCR Home™ platform, which are intended for priority global markets.
Read the article here:

Frequently Asked Questions

What is the total amount awarded to Co-Dx?

Co-Dx was awarded a total of $2.3 million in grants.

Which diseases are the grants for?

The grants are for tuberculosis (TB) and human papillomavirus (HPV) tests.

Who awarded the grants to Co-Dx?

The grants were awarded by the Bill & Melinda Gates Foundation.

What will the funding support?

The funding will support completing tests for the Co-Dx PCR Home™ platform.

What markets are targeted by the Co-Dx tests?

The tests are intended for priority global markets.

Last updated: Jul 18, 2023